A research‑grade peptide blend combining CJC‑1295 (No DAC) and Ipamorelin supplied as a lyophilized vial. This synergistic combination is formulated to stimulate pulsatile growth hormone release and is intended for laboratory and preclinical research into muscle recovery, fat metabolism, sleep and regenerative pathways.
Key Features
- Research grade GHRH and ghrelin receptor agonist blend (99+% purity, third‑party tested)
- Synergistic stimulation of endogenous growth hormone secretion
- Supports preclinical studies of muscle growth, fat loss, recovery and anti‑aging biology
- Supplied lyophilized for investigator‑controlled reconstitution and dosing
- Available format: 5 mg total (5 mg CJC‑1295 + 5 mg Ipamorelin)
Product Specifications
- Product name: CJC‑1295 + Ipamorelin Blend (5 mg + 5 mg) (Purity: 99+% HPLC)
- Growth hormone‑releasing peptide blend (research chemical)
- Supplied in: Lyophilized powder in sterile vial + 3ml bac water
- Administration (research/preclinical): Subcutaneous injection preferred
- Storage (reconstituted): Refrigerate at 2–8 °C
Mechanism of Action
- CJC‑1295 (No DAC) is a GHRH analogue that activates GHRH receptors to promote growth hormone release.
- Ipamorelin is a selective growth hormone secretagogue acting via ghrelin receptors to amplify pulsatile GH secretion.
- In combination, these peptides act synergistically to enhance endogenous GH pulsatility, supporting anabolic, lipolytic and regenerative processes in preclinical models.
Potential Research Applications
- Preclinical models of muscle mass, recovery and atrophy
- Studies of fat loss and metabolic modulation mediated by GH signaling
- Investigations on sleep, recovery and circadian GH dynamics
- Regenerative and anti‑aging pathway research involving GH‑mediated mechanisms
- Combination protocols with exercise or nutritional interventions
Reconstitution Guide
Important: The following are informational reference protocols only. Validate all calculations, aseptic technique and solvent compatibility with your institution’s protocols before use.
(10 mg vial + 3 mL bacteriostatic water)
- Example dosing volumes (U‑100 insulin syringe reference):
- 0.25 mg CJC‑1295 + 0.5mg Ipamorelin peptides (combined): 0.15 mL (15 units)
- 0.5 mg CJC‑1295 + 1mg Ipamorelin peptides: 0.30 mL (30 units)
Suggested Research Dosing Parameters
- Common investigational range for each peptide: 0.25–0.5 mg per dose (combined dosing shown above)
- Typical administration timing used in research: Once daily, preferably before bedtime on an empty stomach to align with endogenous GH release
- Common experimental schedule: 5 days on, 2 days off to maintain responsiveness and cost efficiency
- Cycle lengths in some study designs: 8–12 weeks on with 4–8 weeks off; tapering generally not required
Research Insights
- The blend is used to promote pulsatile GH secretion, which in turn may support muscle repair, fat reduction and improvements in recovery metrics in controlled preclinical studies.
- Individual peptides have demonstrated activity in the 250–1000 mcg (0.25–1.0 mg) range in various investigative contexts; combined protocols aim to leverage complementary mechanisms.
Possible Observations and Adverse Events
- Mild local injection site irritation (rare)
- Temporary water retention or mild edema in some investigational reports
- Mild headache (infrequent)
Storage, Stability and Handling After Reconstitution
- Reconstituted solutions: refrigerate at 2–8 °C and use within 30 days; do not freeze; protect from prolonged light exposure
Safety and Handling
- For laboratory research use only.
- Follow institutional biosafety, handling and waste disposal protocols.
- Use appropriate PPE (gloves, lab coat, eye protection) when handling lyophilized powder and reconstituted solutions.
- Avoid inhalation and contact with skin or eyes. In case of exposure follow institutional procedures.
Frequently Asked Questions
Q: Is 0.25 mg of each peptide a suitable starting research dose?
A: Many protocols reference 0.25 mg per peptide as a conservative investigational starting point; dose selection should be determined by study objectives and approved by oversight bodies.
Q: When is dosing typically administered in research protocols?
A: Nighttime dosing before sleep on an empty stomach is common to align with physiological GH release, though experimental designs may vary.
Q: How soon might effects be observed in preclinical models?
A: Improvements in recovery and body composition markers may be observed within weeks depending on model, dosing and concurrent interventions such as exercise.
Legal and Regulatory Notice
By purchasing this product you confirm that you are acquiring it for lawful research purposes. It is the purchaser’s responsibility to ensure compliance with local laws, institutional policies, ethical and customs requirements. Liability for misuse is disclaimed.
